Sarepta Therapeutics Inc
SRPT15.910USD
-0.510-3.11%
종가 08/01, 16:00（ET）시세는 15분 지연됩니다
1.56B시가총액
손실P/E TTM
자세한 내용은 Sarepta Therapeutics Inc 회사
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
회사 정보
종목 코드 SRPT
회사 이름Sarepta Therapeutics Inc
상장일Jun 04, 1997
설립일2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
직원 수1372
유형Ordinary Share
회계 연도 종료Jun 04
주소215 First Street
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02142
전화16172744000
웹사이트https://www.sarepta.com/
종목 코드 SRPT
상장일Jun 04, 1997
설립일2013
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
사업별USD
이름
수익
비율
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
지역별USD
이름
수익
비율
United States
560.81M
75.29%
Rest of World
50.71M
6.81%
사업별
지역별
사업별USD
이름
수익
비율
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
주식 보유 통계
마지막 업데이트: Sun, Jul 27
마지막 업데이트: Sun, Jul 27
주주
주주 유형
주주
주주
비율
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
주주
주주
비율
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
주주 유형
주주
비율
Investment Advisor
45.71%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
14.66%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.12%
Sovereign Wealth Fund
1.09%
Pension Fund
1.08%
Venture Capital
0.33%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
1025
94.29M
95.95%
-13.91M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital International Investors
9.06M
9.22%
+363.63K
+4.18%
Mar 31, 2025
The Vanguard Group, Inc.
9.01M
9.17%
-59.02K
-0.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
9.06%
-32.03K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
4.07M
4.14%
-1.39K
-0.03%
Mar 31, 2025
Janus Henderson Investors
3.36M
3.42%
-963.48K
-22.26%
Mar 31, 2025
Barry (Richard J)
3.21M
3.27%
+32.60K
+1.02%
May 16, 2025
Avoro Capital Advisors LLC
2.67M
2.72%
+119.28K
+4.67%
Mar 31, 2025
Wellington Management Company, LLP
2.65M
2.69%
+577.85K
+27.93%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.34M
2.38%
-523.68K
-18.28%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
Global X Genomics & Biotechnology ETF
2.7%
First Trust NYSE Arca Biotechnology Index Fund
2.31%
iShares Neuroscience and Healthcare ETF
1.71%
WisdomTree BioRevolution Fund
0.92%
Virtus LifeSci Biotech Products ETF
0.91%
Harbor Human Capital Factor Unconstrained ETF
0.87%
VanEck Biotech ETF
0.79%
Tema Neuroscience and Mental Health ETF
0.72%
SPDR S&P Biotech ETF
0.66%
Invesco S&P MidCap 400 Pure Growth ETF
0.54%
더 보기
Global X Genomics & Biotechnology ETF
비율2.7%
First Trust NYSE Arca Biotechnology Index Fund
비율2.31%
iShares Neuroscience and Healthcare ETF
비율1.71%
WisdomTree BioRevolution Fund
비율0.92%
Virtus LifeSci Biotech Products ETF
비율0.91%
Harbor Human Capital Factor Unconstrained ETF
비율0.87%
VanEck Biotech ETF
비율0.79%
Tema Neuroscience and Mental Health ETF
비율0.72%
SPDR S&P Biotech ETF
비율0.66%
Invesco S&P MidCap 400 Pure Growth ETF
비율0.54%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
